Extreme drug tolerance of mycobacterium tuberculosis in Caseum

Jansy P. Sarathy, Laura E. Via, Danielle Weiner, Landry Blanc, Helena Boshoff, Eliseo Eugenin, Clifton E. Barry, Véronique A. Dartois

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Tuberculosis (TB) recently became the leading infectious cause of death in adults, while attempts to shorten therapy have largely failed. Dormancy, persistence, and drug tolerance are among the factors driving the long therapy duration. Assays to measure in situ drug susceptibility of Mycobacterium tuberculosis bacteria in pulmonary lesions are needed if we are to discover new fast-acting regimens and address the global TB threat. Here we take a first step toward this goal and describe an ex vivo assay developed to measure the cidal activity of anti-TB drugs against M. tuberculosis bacilli present in cavity caseum obtained from rabbits with active TB. We show that caseum M. tuberculosis bacilli are largely nonreplicating, maintain viability over the course of the assay, and exhibit extreme tolerance to many first- and second-line TB drugs. Among the drugs tested, only the rifamycins fully sterilized caseum. A similar trend of phenotypic drug resistance was observed in the hypoxia- and starvation-induced nonreplicating models, but with notable qualitative and quantitative differences: (i) caseum M. tuberculosis exhibits higher drug tolerance than nonreplicating M. tuberculosis in the Wayne and Loebel models, and (ii) pyrazinamide is cidal in caseum but has no detectable activity in these classic nonreplicating assays. Thus, ex vivo caseum constitutes a unique tool to evaluate drug potency against slowly replicating or nonreplicating bacilli in their native caseous environment. Intracaseum cidal concentrations can now be related to the concentrations achieved in the necrotic foci of granulomas and cavities to establish correlations between clinical outcome and lesion-centered pharmacokinetics-pharmacodynamics (PK-PD) parameters.

Original languageEnglish (US)
Article numbere02057-17
JournalAntimicrobial Agents and Chemotherapy
Volume62
Issue number2
DOIs
StatePublished - Feb 1 2018
Externally publishedYes

Fingerprint

Drug Tolerance
Mycobacterium tuberculosis
Tuberculosis
Bacillus
Pharmaceutical Preparations
Rifamycins
Pyrazinamide
Starvation
Granuloma
Drug Resistance
Cause of Death
Pharmacokinetics
Rabbits
Bacteria
Lung
Therapeutics

Keywords

  • Caseum
  • Drug tolerance
  • In vitro potency model
  • Mycobacterium tuberculosis
  • Persistence
  • Pharmacokinetics-pharmacodynamics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Sarathy, J. P., Via, L. E., Weiner, D., Blanc, L., Boshoff, H., Eugenin, E., ... Dartois, V. A. (2018). Extreme drug tolerance of mycobacterium tuberculosis in Caseum. Antimicrobial Agents and Chemotherapy, 62(2), [e02057-17]. https://doi.org/10.1128/AAC.02266-17

Extreme drug tolerance of mycobacterium tuberculosis in Caseum. / Sarathy, Jansy P.; Via, Laura E.; Weiner, Danielle; Blanc, Landry; Boshoff, Helena; Eugenin, Eliseo; Barry, Clifton E.; Dartois, Véronique A.

In: Antimicrobial Agents and Chemotherapy, Vol. 62, No. 2, e02057-17, 01.02.2018.

Research output: Contribution to journalArticle

Sarathy, JP, Via, LE, Weiner, D, Blanc, L, Boshoff, H, Eugenin, E, Barry, CE & Dartois, VA 2018, 'Extreme drug tolerance of mycobacterium tuberculosis in Caseum', Antimicrobial Agents and Chemotherapy, vol. 62, no. 2, e02057-17. https://doi.org/10.1128/AAC.02266-17
Sarathy, Jansy P. ; Via, Laura E. ; Weiner, Danielle ; Blanc, Landry ; Boshoff, Helena ; Eugenin, Eliseo ; Barry, Clifton E. ; Dartois, Véronique A. / Extreme drug tolerance of mycobacterium tuberculosis in Caseum. In: Antimicrobial Agents and Chemotherapy. 2018 ; Vol. 62, No. 2.
@article{adca0a660d5a42acb98ca07c740946ef,
title = "Extreme drug tolerance of mycobacterium tuberculosis in Caseum",
abstract = "Tuberculosis (TB) recently became the leading infectious cause of death in adults, while attempts to shorten therapy have largely failed. Dormancy, persistence, and drug tolerance are among the factors driving the long therapy duration. Assays to measure in situ drug susceptibility of Mycobacterium tuberculosis bacteria in pulmonary lesions are needed if we are to discover new fast-acting regimens and address the global TB threat. Here we take a first step toward this goal and describe an ex vivo assay developed to measure the cidal activity of anti-TB drugs against M. tuberculosis bacilli present in cavity caseum obtained from rabbits with active TB. We show that caseum M. tuberculosis bacilli are largely nonreplicating, maintain viability over the course of the assay, and exhibit extreme tolerance to many first- and second-line TB drugs. Among the drugs tested, only the rifamycins fully sterilized caseum. A similar trend of phenotypic drug resistance was observed in the hypoxia- and starvation-induced nonreplicating models, but with notable qualitative and quantitative differences: (i) caseum M. tuberculosis exhibits higher drug tolerance than nonreplicating M. tuberculosis in the Wayne and Loebel models, and (ii) pyrazinamide is cidal in caseum but has no detectable activity in these classic nonreplicating assays. Thus, ex vivo caseum constitutes a unique tool to evaluate drug potency against slowly replicating or nonreplicating bacilli in their native caseous environment. Intracaseum cidal concentrations can now be related to the concentrations achieved in the necrotic foci of granulomas and cavities to establish correlations between clinical outcome and lesion-centered pharmacokinetics-pharmacodynamics (PK-PD) parameters.",
keywords = "Caseum, Drug tolerance, In vitro potency model, Mycobacterium tuberculosis, Persistence, Pharmacokinetics-pharmacodynamics",
author = "Sarathy, {Jansy P.} and Via, {Laura E.} and Danielle Weiner and Landry Blanc and Helena Boshoff and Eliseo Eugenin and Barry, {Clifton E.} and Dartois, {V{\'e}ronique A.}",
year = "2018",
month = "2",
day = "1",
doi = "10.1128/AAC.02266-17",
language = "English (US)",
volume = "62",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "2",

}

TY - JOUR

T1 - Extreme drug tolerance of mycobacterium tuberculosis in Caseum

AU - Sarathy, Jansy P.

AU - Via, Laura E.

AU - Weiner, Danielle

AU - Blanc, Landry

AU - Boshoff, Helena

AU - Eugenin, Eliseo

AU - Barry, Clifton E.

AU - Dartois, Véronique A.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Tuberculosis (TB) recently became the leading infectious cause of death in adults, while attempts to shorten therapy have largely failed. Dormancy, persistence, and drug tolerance are among the factors driving the long therapy duration. Assays to measure in situ drug susceptibility of Mycobacterium tuberculosis bacteria in pulmonary lesions are needed if we are to discover new fast-acting regimens and address the global TB threat. Here we take a first step toward this goal and describe an ex vivo assay developed to measure the cidal activity of anti-TB drugs against M. tuberculosis bacilli present in cavity caseum obtained from rabbits with active TB. We show that caseum M. tuberculosis bacilli are largely nonreplicating, maintain viability over the course of the assay, and exhibit extreme tolerance to many first- and second-line TB drugs. Among the drugs tested, only the rifamycins fully sterilized caseum. A similar trend of phenotypic drug resistance was observed in the hypoxia- and starvation-induced nonreplicating models, but with notable qualitative and quantitative differences: (i) caseum M. tuberculosis exhibits higher drug tolerance than nonreplicating M. tuberculosis in the Wayne and Loebel models, and (ii) pyrazinamide is cidal in caseum but has no detectable activity in these classic nonreplicating assays. Thus, ex vivo caseum constitutes a unique tool to evaluate drug potency against slowly replicating or nonreplicating bacilli in their native caseous environment. Intracaseum cidal concentrations can now be related to the concentrations achieved in the necrotic foci of granulomas and cavities to establish correlations between clinical outcome and lesion-centered pharmacokinetics-pharmacodynamics (PK-PD) parameters.

AB - Tuberculosis (TB) recently became the leading infectious cause of death in adults, while attempts to shorten therapy have largely failed. Dormancy, persistence, and drug tolerance are among the factors driving the long therapy duration. Assays to measure in situ drug susceptibility of Mycobacterium tuberculosis bacteria in pulmonary lesions are needed if we are to discover new fast-acting regimens and address the global TB threat. Here we take a first step toward this goal and describe an ex vivo assay developed to measure the cidal activity of anti-TB drugs against M. tuberculosis bacilli present in cavity caseum obtained from rabbits with active TB. We show that caseum M. tuberculosis bacilli are largely nonreplicating, maintain viability over the course of the assay, and exhibit extreme tolerance to many first- and second-line TB drugs. Among the drugs tested, only the rifamycins fully sterilized caseum. A similar trend of phenotypic drug resistance was observed in the hypoxia- and starvation-induced nonreplicating models, but with notable qualitative and quantitative differences: (i) caseum M. tuberculosis exhibits higher drug tolerance than nonreplicating M. tuberculosis in the Wayne and Loebel models, and (ii) pyrazinamide is cidal in caseum but has no detectable activity in these classic nonreplicating assays. Thus, ex vivo caseum constitutes a unique tool to evaluate drug potency against slowly replicating or nonreplicating bacilli in their native caseous environment. Intracaseum cidal concentrations can now be related to the concentrations achieved in the necrotic foci of granulomas and cavities to establish correlations between clinical outcome and lesion-centered pharmacokinetics-pharmacodynamics (PK-PD) parameters.

KW - Caseum

KW - Drug tolerance

KW - In vitro potency model

KW - Mycobacterium tuberculosis

KW - Persistence

KW - Pharmacokinetics-pharmacodynamics

UR - http://www.scopus.com/inward/record.url?scp=85041046554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041046554&partnerID=8YFLogxK

U2 - 10.1128/AAC.02266-17

DO - 10.1128/AAC.02266-17

M3 - Article

VL - 62

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 2

M1 - e02057-17

ER -